XLV vs. IDNA
XLV (State Street Health Care Select Sector SPDR ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds - XLV tracks the Health Care Select Sector Index while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. Over the past 5 years, XLV returned 6.19%/yr vs -7.75%/yr for IDNA. A 0.56 correlation means they provide meaningful diversification when combined. XLV charges 0.08%/yr vs 0.47%/yr for IDNA.
Performance
XLV vs. IDNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XLV achieves a -1.35% return, which is significantly lower than IDNA's 14.39% return.
XLV
- 1D
- 3.07%
- 1M
- 4.67%
- YTD
- -1.35%
- 6M
- -0.35%
- 1Y
- 16.13%
- 3Y*
- 6.92%
- 5Y*
- 6.19%
- 10Y*
- 9.48%
IDNA
- 1D
- 3.70%
- 1M
- 1.49%
- YTD
- 14.39%
- 6M
- 11.58%
- 1Y
- 45.52%
- 3Y*
- 8.39%
- 5Y*
- -7.75%
- 10Y*
- —
XLV vs. IDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
XLV State Street Health Care Select Sector SPDR ETF | -1.35% | 14.50% | 2.47% | 2.07% | -2.08% | 26.04% | 13.30% | 13.51% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 14.39% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
Correlation
The correlation between XLV and IDNA is 0.60, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.60 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.55 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.56 |
Correlation (All Time) Calculated using the full available price history since Jun 14, 2019 | 0.56 |
The correlation between XLV and IDNA has been stable across timeframes, ranging from 0.55 to 0.60 - a consistent structural relationship.
XLV vs. IDNA - Sectors Allocation Comparison
Sectors
XLV
IDNA
Healthcare
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
XLV
IDNA
Basic Materials
XLV
-
IDNA
-
Communication Services
XLV
-
IDNA
-
Consumer Cyclical
XLV
-
IDNA
-
Consumer Defensive
XLV
-
IDNA
-
Energy
XLV
-
IDNA
-
Financial Services
XLV
-
IDNA
-
Industrials
XLV
-
IDNA
Real Estate
XLV
-
IDNA
-
Technology
XLV
-
IDNA
-
Utilities
XLV
-
IDNA
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XLV vs. IDNA — Risk / Return Rank
XLV
IDNA
XLV vs. IDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for State Street Health Care Select Sector SPDR ETF (XLV) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XLV | IDNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.77 | ||
| Sortino ratioReturn per unit of downside risk | -0.93 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.30 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 1.55 | 4.29 | -2.74 |
| Martin ratioReturn relative to average drawdown | 3.73 | 12.20 | -8.47 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| XLV | IDNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.08 | 1.85 | -0.77 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.42 | -0.27 | +0.69 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.57 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.46 | 0.12 | +0.34 |
Drawdowns
XLV vs. IDNA - Drawdown Comparison
The maximum XLV drawdown since its inception was -39.17%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for XLV and IDNA.
Loading charts...
Drawdown Indicators
| XLV | IDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -39.17% | -68.26% | +29.09% |
Max Drawdown (1Y)Largest decline over 1 year | -10.47% | -10.66% | +0.19% |
Max Drawdown (3Y)Largest decline over 3 years | -17.11% | -29.73% | +12.62% |
Max Drawdown (5Y)Largest decline over 5 years | -17.11% | -68.26% | +51.15% |
Max Drawdown (10Y)Largest decline over 10 years | -28.40% | — | — |
Current DrawdownCurrent decline from peak | -4.68% | -43.60% | +38.92% |
Average DrawdownAverage peak-to-trough decline | -7.12% | -36.25% | +29.13% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.33% | 3.74% | +0.59% |
Volatility
XLV vs. IDNA - Volatility Comparison
The current volatility for State Street Health Care Select Sector SPDR ETF (XLV) is 5.04%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 8.09%. This indicates that XLV experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XLV | IDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.04% | 8.09% | -3.05% |
Volatility (6M)Calculated over the trailing 6-month period | 10.67% | 18.14% | -7.47% |
Volatility (1Y)Calculated over the trailing 1-year period | 14.97% | 24.71% | -9.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 14.76% | 28.46% | -13.70% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 16.57% | 29.55% | -12.98% |
XLV vs. IDNA - Expense Ratio Comparison
XLV has a 0.08% expense ratio, which is lower than IDNA's 0.47% expense ratio.
Dividends
XLV vs. IDNA - Dividend Comparison
XLV's dividend yield for the trailing twelve months is around 1.65%, more than IDNA's 1.03% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.03% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% |
XLV State Street Health Care Select Sector SPDR ETF | 1.65% | 1.60% | 1.67% | 1.59% | 1.47% | 1.33% | 1.49% | 2.17% | 1.57% | 1.47% | 1.60% | 1.43% |
Frequently Asked Questions
XLV and IDNA have a correlation of 0.60, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
IDNA has higher volatility (8.09%) compared to XLV (5.04%). In terms of maximum drawdown, XLV dropped -39.17% vs IDNA's -68.26%.
On 5-year performance, XLV leads with 6.19% vs -7.75% for IDNA. On fees, XLV is cheaper at 0.08% per year. On volatility, XLV has been the lower-risk option at 5.04%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, XLV has performed better with a 6.19% return vs -7.75%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XLV is cheaper with a 0.08% expense ratio, compared with 0.47% for IDNA.
XLV has the higher dividend yield at 1.65%, compared with 1.03% for IDNA.
XLV tracks Health Care Select Sector Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: State Street and iShares. Their fees differ too: 0.08% for XLV and 0.47% for IDNA.
IDNA currently has the higher Sharpe Ratio (1.85 vs 1.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XLV and IDNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer